This article is more than 5 years old. Information may no longer be current.

Novel anti-VEGF agent improves vision, reduces macular thickness in patients with DME

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia — Use of an investigational anti-VEGF agent reduced central retinal thickness and improved visual acuity compared with laser in a phase 2 study of patients with diabetic macular edema.

Victor H. Gonzalez

Patients in the DA VINCI study were randomized to one of four dose strengths of VEGF Trap-Eye (Regeneron) plus sham laser or laser plus sham injection, Victor H. Gonzalez, MD, said at the American Society of Retina Specialists annual meeting.

Gains in visual acuity from baseline were 11.4 ETDRS letters, 10.3 ETDRS letters, 8.5 ETDRS letters and 8.6 ETDRS letters in groups treated with a 2-mg dose every 4 weeks, a 2-mg dose as needed, a 2-mg dose every 8 weeks and a 0.5-mg dose every 4 weeks, respectively. There was a gain of 2.5 letters observed in the laser group.

Change in central retinal thickness was also statistically significantly greater among the VEGF Trap-Eye groups compared with laser, Dr. Gonzalez said.

"The ability of VEGF Trap-Eye to significantly improve vision and decrease retinal thickness in patients with diabetic macular edema is encouraging," Dr. Gonzalez said.